Introduction: Who Should Undergo Diagnostics

Anyone experiencing unusual symptoms that might suggest lymphoma should speak with their doctor as soon as possible. Double-hit lymphoma is a type of non-Hodgkin lymphoma, which means it develops from white blood cells called B lymphocytes or B cells. These cells are normally part of the immune system, but in double-hit lymphoma, they grow abnormally and cause disease.^[4]

People who notice certain warning signs should seek medical attention promptly. Common symptoms include swollen lymph nodes that don’t go away, persistent fevers without an obvious cause, night sweats that soak through clothing or bedding, and unexplained weight loss. Other signs may include extreme tiredness, trouble breathing, or loss of appetite.^[4] Because double-hit lymphoma tends to be aggressive and can progress rapidly, early evaluation is important.

Double-hit lymphoma primarily affects older adults, though it can occur at any age. It is slightly more common in males than females.^[4] This type of cancer often presents with rapidly progressive disease and is commonly found at an advanced stage when first diagnosed.^[12] Many patients already have cancer that has spread to multiple areas of the body by the time they receive their diagnosis.

Classic Diagnostic Methods

Diagnosing double-hit lymphoma involves several steps, starting with a thorough physical examination and medical history. However, the definitive diagnosis requires specialized laboratory tests that look at the genetic makeup of cancer cells. The process typically begins when a doctor notices enlarged lymph nodes or other suspicious findings during an examination or on imaging studies.

Biopsy and Tissue Analysis

The most important diagnostic procedure is a biopsy, where doctors remove a sample of tissue from a suspicious lymph node or mass. In some cases, a fine-needle aspiration may be performed first, but this is often insufficient for a complete diagnosis. Most patients require an excisional biopsy, where an entire lymph node is removed for examination. This larger sample provides pathologists with enough material to perform all necessary tests.^[1]

Once the tissue sample is collected, specialized doctors called pathologists examine it under a microscope. They look at the shape and size of the cells, as well as how they are arranged. Double-hit lymphoma cells often appear as aggressive, fast-growing B cells. The pathologists also perform tests to identify specific proteins on the surface of these cells, such as CD20, CD10, BCL2, and MYC. These proteins help distinguish double-hit lymphoma from other types of lymphoma.^[3][9]

Genetic Testing: The Key to Diagnosis

What truly defines double-hit lymphoma is not just how the cells look, but the genetic changes they contain. The name “double-hit” comes from the presence of two specific genetic abnormalities called rearrangements or translocations. These occur when pieces of chromosomes break off and combine in abnormal ways.^[4]

In double-hit lymphoma, one rearrangement always involves a gene called MYC. This gene normally helps control cell growth and division. The second rearrangement involves either the BCL2 gene or, less commonly, the BCL6 gene. BCL2 and BCL6 normally help regulate cell death, ensuring that old or damaged cells die when they should. When these genes are rearranged, cells divide too rapidly and fail to die when they should, leading to cancer.^[3][4]

To detect these gene rearrangements, laboratories use a technique called fluorescence in situ hybridization, or FISH. This molecular test allows doctors to check for specific changes in chromosomes under a microscope. The FISH test is essential for confirming a diagnosis of double-hit lymphoma because it can definitively identify the presence of both MYC and BCL2 or BCL6 rearrangements.^[3][9]

When all three genes—MYC, BCL2, and BCL6—are rearranged in the same patient, the cancer is called triple-hit lymphoma. This is even rarer but is treated similarly to double-hit lymphoma.^[4]

Classification and Naming

The medical community has refined how it classifies double-hit lymphoma over time. In 2016, the World Health Organization officially designated this cancer as its own distinct category called high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements. Previously, it was often grouped together with other types of B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma.^[3][5]

In fact, about five percent of patients diagnosed with DLBCL actually have double-hit lymphoma when genetic testing is performed. Similarly, a significant portion of Burkitt lymphoma cases—between 32 and 78 percent—also have these dual gene rearrangements. Despite sharing some features with these other lymphomas, double-hit lymphoma behaves differently and requires different treatment approaches, which is why accurate diagnosis through genetic testing is so crucial.^[3]

Additional Diagnostic Tests

Once a diagnosis of double-hit lymphoma is suspected or confirmed, doctors order additional tests to determine how far the disease has spread. These staging tests help doctors understand the extent of cancer in the body and plan appropriate treatment. Common staging tests include blood work to check for abnormal cell counts and elevated levels of an enzyme called lactate dehydrogenase, which is often high in aggressive lymphomas.^[9]

Imaging studies are also essential for staging. A PET-CT scan (positron emission tomography combined with computed tomography) is commonly used because it can show both the location and metabolic activity of cancer cells throughout the body. This test uses a small amount of radioactive sugar that cancer cells absorb more readily than normal cells, making them visible on the scan. Many patients with double-hit lymphoma are found to have widespread disease affecting lymph nodes on both sides of the diaphragm or involvement of organs outside the lymphatic system.^[9]

A bone marrow biopsy may be performed to check whether cancer cells have spread to the bone marrow, which is where blood cells are made. This involves taking a small sample of bone marrow, usually from the hip bone, using a special needle. The procedure is done with local anesthesia to minimize discomfort.^[9]

Diagnostics for Clinical Trial Qualification

When patients with double-hit lymphoma are being considered for enrollment in clinical trials, they typically undergo the same diagnostic tests used for standard diagnosis, but these are performed according to strict guidelines to ensure consistency across all study participants. Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to manage this aggressive cancer.

For clinical trial enrollment, confirmation of the diagnosis through genetic testing is almost always required. Trials specifically designed for double-hit lymphoma or high-grade B-cell lymphoma will require documented evidence of MYC rearrangement along with BCL2 or BCL6 rearrangement, typically confirmed by FISH testing. This ensures that all patients in the study have the same type of disease, which makes the results more reliable.^[3]

Clinical trials also typically require detailed staging information obtained through PET-CT scans and bone marrow biopsies. The stage of disease, measured by the extent of cancer spread, often determines whether a patient is eligible for a particular study. Many trials also use scoring systems such as the International Prognostic Index (IPI), which considers factors like age, stage of disease, blood test results, and performance status to predict outcomes.^[9]

Blood tests are standard for clinical trial screening. These include complete blood counts to measure different types of blood cells, tests of liver and kidney function, and measurement of lactate dehydrogenase levels. Some trials may also require tests to check for certain infections, such as HIV, hepatitis B, or hepatitis C, as these can affect both disease behavior and treatment safety.^[9]

Performance status is another key factor assessed for clinical trial eligibility. Doctors use standardized scales, such as the Eastern Cooperative Oncology Group (ECOG) performance status, to rate how well a patient can perform daily activities. This helps determine whether a patient is healthy enough to tolerate the experimental treatments being studied.^[9]

Some clinical trials require additional specialized testing beyond standard diagnostics. For example, trials studying targeted therapies may need tests to measure the levels of specific proteins on cancer cells, such as CD19, which is targeted by certain immunotherapy treatments. Other studies might examine additional genetic or molecular features of the cancer cells to identify patients most likely to benefit from experimental drugs.^[11]

Before enrolling in a clinical trial, patients undergo a thorough evaluation to ensure they meet all eligibility criteria. This often includes repeating some tests even if they were done recently, to provide up-to-date baseline information that researchers can use to measure how well the treatment works. The goal is to ensure patient safety and to gather accurate data that will help improve future care for others with double-hit lymphoma.